产品
编 号：F291833
分子式：C14H16N4NaO8.5
分子量：399.31
分子式：C14H16N4NaO8.5
分子量：399.31
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
100mg
询价
询价
500mg
询价
询价
结构图
CAS No: 24868-20-0
产品详情
生物活性：
Dantrolene sodium hemiheptahydrate is an orally active, non-competitive glutathione reductase inhibitor with a Ki of 111.6 μM and an IC50 of 52.3 μM. Dantrolene sodium hemiheptahydrate is a ryanodine receptor (RyR) antagonist and Ca2+ signaling stabilizer. Dantrolene sodium hemiheptahydrate is a direct-acting skeletal muscle relaxant. Dantrolene sodium hemiheptahydrate can be used for the research of muscle spasticity, malignant hyperthermia, Huntington's disease and other neuroleptic malignant syndrome.
体内研究：
Dantrolene (5 mg/kg；每周口服两次) sodium hemiheptahydrate 可改善平衡木行走和步态行走测定中的表现。 Dantrolene (10mg/kg；腹腔；每周三天；持续 40-60 天) sodium hemiheptahydrate 可显着改善步态，降低 LC3-II 水平，改善线粒体 ATP 生成并减少大脑炎症。Dantrolene sodium hemiheptahydrate 降低神经病性戈谢病小鼠大脑中的自噬和 CALM (钙调蛋白)的表达。 Animal Model:YAC128 transgenic mice (FVBN/NJ background strain) and WT mice
Dosage:5 mg/kg
Administration:Fed orally twice per week from 2 to 11.5 months of age
Result:Resulted in significantly improved performance in the beam-walking and gait-walking assays. Significantly reduced the loss of NeuN-positive striatal neurons and reduced formation of Httexp nuclear aggregates.
体外研究：
Dantrolene (60 μM；第 1 天和第 3 天) sodium hemiheptahydrate 显着抑制 paVIC 中的 ACTA2 表达并上调 RUNX2 表达。 Dantrolene (60 μM；过夜预处理) sodium hemiheptahydrate 可抑制猪主动脉瓣间质细胞中 LPC 诱导的钙流。Dantrolene (10、30、60 μM) sodium hemiheptahydrate 可抑制 10 μM 溶血磷脂酰胆碱 (LPC) 引起的 paVIC 钙化结节的形成。
Dantrolene sodium hemiheptahydrate is an orally active, non-competitive glutathione reductase inhibitor with a Ki of 111.6 μM and an IC50 of 52.3 μM. Dantrolene sodium hemiheptahydrate is a ryanodine receptor (RyR) antagonist and Ca2+ signaling stabilizer. Dantrolene sodium hemiheptahydrate is a direct-acting skeletal muscle relaxant. Dantrolene sodium hemiheptahydrate can be used for the research of muscle spasticity, malignant hyperthermia, Huntington's disease and other neuroleptic malignant syndrome.
体内研究：
Dantrolene (5 mg/kg；每周口服两次) sodium hemiheptahydrate 可改善平衡木行走和步态行走测定中的表现。 Dantrolene (10mg/kg；腹腔；每周三天；持续 40-60 天) sodium hemiheptahydrate 可显着改善步态，降低 LC3-II 水平，改善线粒体 ATP 生成并减少大脑炎症。Dantrolene sodium hemiheptahydrate 降低神经病性戈谢病小鼠大脑中的自噬和 CALM (钙调蛋白)的表达。 Animal Model:YAC128 transgenic mice (FVBN/NJ background strain) and WT mice
Dosage:5 mg/kg
Administration:Fed orally twice per week from 2 to 11.5 months of age
Result:Resulted in significantly improved performance in the beam-walking and gait-walking assays. Significantly reduced the loss of NeuN-positive striatal neurons and reduced formation of Httexp nuclear aggregates.
体外研究：
Dantrolene (60 μM；第 1 天和第 3 天) sodium hemiheptahydrate 显着抑制 paVIC 中的 ACTA2 表达并上调 RUNX2 表达。 Dantrolene (60 μM；过夜预处理) sodium hemiheptahydrate 可抑制猪主动脉瓣间质细胞中 LPC 诱导的钙流。Dantrolene (10、30、60 μM) sodium hemiheptahydrate 可抑制 10 μM 溶血磷脂酰胆碱 (LPC) 引起的 paVIC 钙化结节的形成。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备